Therapeutic control of B cell activation via recruitment of Fcγ receptor IIb (CD32B) inhibitory function with a novel bispecific antibody scaffold

Arthritis and Rheumatism

Volumn 62, Issue 7, 2010, Pages 1933-1943

  Veri, Maria Concetta ^a   Burke, Stephen ^a   Huang, Ling ^a   Li, Hua ^a   Gorlatov, Sergey ^a   Tuaillon, Nadine ^a   Rainey, G Jonah ^a   Ciccarone, Valentina ^a   Zhang, Tengfei ^a   Shah, Kay ^a   Jin, Linda ^a   Ning, Lida ^a   Minor, Tamara ^a   Moore, Paul A ^a   Koenig, Scott ^a   Johnson, Syd ^a   Bonvini, Ezio ^a  

^a Analytical Sciences   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BISPECIFIC ANTIBODY; CD79B ANTIGEN; DUAL AFFINITY RETARGETING MOLECULE; FC RECEPTOR IIB; MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL MODEL; ANTIBODY ENGINEERING; ARTHRITIS; ARTICLE; B LYMPHOCYTE ACTIVATION; BETA CHAIN; CALCIUM MOBILIZATION; COLLAGEN INDUCED ARTHRITIS; CONTROLLED STUDY; DBA 1 MOUSE; DISEASE CONTROL; DISEASE SEVERITY; HUMAN; HUMAN CELL; IMMUNOGLOBULIN PRODUCTION; IN VITRO STUDY; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RECEPTOR BINDING; SIGNAL TRANSDUCTION;

ANIMALS; ANTIBODIES, BISPECIFIC; ANTIBODIES, MONOCLONAL; ANTIGEN-ANTIBODY COMPLEX; ANTIGENS, CD79; ARTHRITIS, EXPERIMENTAL; B-LYMPHOCYTES; CELL PROLIFERATION; CELLS, CULTURED; DIMERIZATION; FEMALE; HUMANS; IMMUNOGLOBULINS; IMMUNOSUPPRESSIVE AGENTS; LYMPHOCYTE ACTIVATION; MALE; MICE; MICE, KNOCKOUT; RECEPTORS, IGG; SIGNAL TRANSDUCTION; SPLEEN; TISSUE SCAFFOLDS;

EID: 77954232707     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.27477     Document Type: Article

References (33)

1. Nimmerjahn F, Ravetch JV. Fcγ receptors as regulators of immune responses. Nat Rev Immunol 2008;8:34-47.
2. Daeron M, Latour S, Malbec O, Espinosa E, Pina P, Pasmans S, et al. The same tyrosine-based inhibition motif, in the intracytoplasmic domain of Fcγ RIIB, regulates negatively BCR-, TCR-, and FcR-dependent cell activation. Immunity 1995;3:635-46.
3. Crowley JE, Stadanlick JE, Cambier JC, Cancro MP. FcγRIIB signals inhibit BLyS signaling and BCR-mediated BLyS receptor up-regulation. Blood 2009;113:1464-73.
4. Coggeshall KM. Inhibitory signaling by B cell FcγRIIb. Curr Opin Immunol 1998;10:306-12.
5. Bolland S, Ravetch JV. Spontaneous autoimmune disease in FcγRIIB-deficient mice results from strain-specific epistasis. Immunity 2000;13:277-85.
6. -/- mice. J Exp Med 2002;195:1167-74.
7. Popa C, Leandro MJ, Cambridge G, Edwards JC. Repeated B lymphocyte depletion with rituximab in rheumatoid arthritis over 7 yrs. Rheumatology (Oxford) 2007;46:626-30.
8. Mease PJ, Revicki DA, Szechinski J, Greenwald M, Kivitz A, Barile-Fabris L, et al. Improved health-related quality of life for patients with active rheumatoid arthritis receiving rituximab: results of the Dose-Ranging Assessment: International Clinical Evaluation of Rituximab in Rheumatoid Arthritis (DANCER) Trial. J Rheumatol 2008;35:20-30.
9. Veri MC, Gorlatov S, Li H, Burke S, Johnson S, Stavenhagen J, et al. Monoclonal antibodies capable of discriminating the human inhibitory Fcγ-receptor IIB (CD32B) from the activating Fcγ-receptor IIA (CD32A): biochemical, biological and functional characterization. Immunology 2007;121:392-404.
10. Nakamura T, Kubagawa H, Cooper MD. Heterogeneity of immunoglobulin- associated molecules on human B cells identified by monoclonal antibodies. Proc Natl Acad Sci U S A 1992;89:8522-6.
11. Olafsen T, Cheung CW, Yazaki PJ, Li L, Sundaresan G, Gambhir SS, et al. Covalent disulfide-linked anti-CEA diabody allows site-specific conjugation and radiolabeling for tumor targeting applications. Protein Eng Des Sel 2004;17:21-7.
12. Ono M, Bolland S, Tempst P, Ravetch JV. Role of the inositol phosphatase SHIP in negative regulation of the immune system by the receptor FcγRIIB. Nature 1996;383:263-6.
13. Ono M, Okada H, Bolland S, Yanagi S, Kurosaki T, Ravetch JV. Deletion of SHIP or SHP-1 reveals two distinct pathways for inhibitory signaling. Cell 1997;90:293-301.
14. Sarkar S, Schlottmann K, Cooney D, Coggeshall KM. Negative signaling via FcγRIIB1 in B cells blocks phospholipase Cγ2 tyrosine phosphorylation but not Syk or Lyn activation. J Biol Chem 1996;271:20182-6. (Pubitemid 26281775)
15. Isnardi I, Lesourne R, Bruhns P, Fridman WH, Cambier JC, Daeron M. Two distinct tyrosine-based motifs enable the inhibitory receptor FcγRIIB to cooperatively recruit the inositol phosphatases SHIP1/2 and the adapters Grb2/Grap. J Biol Chem 2004;279:51931-8. (Pubitemid 39656561)
16. Billadeau DD, Leibson PJ. ITAMs versus ITIMs: striking a balance during cell regulation. J Clin Invest 2002;109:161-8.
17. Marshall AJ, Niiro H, Yun TJ, Clark EA. Regulation of B-cell activation and differentiation by the phosphatidylinositol 3-kinase and phospholipase Cγ pathway. Immunol Rev 2000;176:30-46.
18. Gessner JE, Heiken H, Tamm A, Schmidt RE. The IgG Fc receptor family. Ann Hematol 1998;76:231-48.
19. Svensson L, Jirholt J, Holmdahl R, Jansson L. B cell-deficient mice do not develop type II collagen-induced arthritis (CIA). Clin Exp Immunol 1998;111:521-6. (Pubitemid 28160894)
20. Diaz de Stahl T, Andren M, Martinsson P, Verbeek JS, Kleinau S. Expression of FcγRIII is required for development of collagen-induced arthritis. Eur J Immunol 2002;32:2915-22. (Pubitemid 35238185)
21. Kleinau S, Martinsson P, Heyman B. Induction and suppression of collagen-induced arthritis is dependent on distinct Fcγ receptors. J Exp Med 2000;191:1611-6. (Pubitemid 30257357)
22. Song X, Shapiro S, Goldman DL, Casadevall A, Scharff M, Lee SC. Fcγ receptor I- and III-mediated macrophage inflammatory protein 1α induction in primary human and murine microglia. Infect Immun 2002;70:5177-84.
23. Boot JH, Geerts ME, Aarden LA. Functional polymorphisms of Fc receptors in human monocyte-mediated cytotoxicity towards erythrocytes induced by murine isotype switch variants. J Immunol 1989;142:1217-23.
24. Koyama M, Ishihara K, Karasuyama H, Cordell JL, Iwamoto A, Nakamura T. CD79α/CD79β heterodimers are expressed on pro-B cell surfaces without associated μ heavy chain. Int Immunol 1997;9:1767-72. (Pubitemid 27494139)
25. Ravetch JV, Bolland S. IgG Fc receptors. Annu Rev Immunol 2001;19:275-90.
26. Zhu D, Kepley CL, Zhang M, Zhang K, Saxon A. A novel human immunoglobulin Fcγ-Fcε bifunctional fusion protein inhibits Fcε RI-mediated degranulation. Nat Med 2002;8:518-21.
27. Zhu D, Kepley CL, Zhang K, Terada T, Yamada T, Saxon A. A chimeric human-cat fusion protein blocks cat-induced allergy. Nat Med 2005;11:446-9.
28. Chu SY, Vostiar I, Karki S, Moore GL, Lazar GA, Pong E, et al. Inhibition of B cell receptor-mediated activation of primary human B cells by coengagement of CD19 and FcγRIIb with Fc-engineered antibodies. Mol Immunol 2008;45:3926-33.
29. Kono H, Kyogoku C, Suzuki T, Tsuchiya N, Honda H, Yamamoto K, et al. FcγRIIB Ile232Thr transmembrane polymorphism associated with human systemic lupus erythematosus decreases affinity to lipid rafts and attenuates inhibitory effects on B cell receptor signaling. Hum Mol Genet 2005;14:2881-92.
30. Xiang Z, Cutler AJ, Brownlie RJ, Fairfax K, Lawlor KE, Severinson E, et al. FcγRIIb controls bone marrow plasma cell persistence and apoptosis. Nat Immunol 2007;8:419-29.
31. Pearse RN, Kawabe T, Bolland S, Guinamard R, Kurosaki T, Ravetch JV. SHIP recruitment attenuates FcγRIIB-induced B cell apoptosis. Immunity 1999;10:753-60.
32. b mice susceptible to collagen-induced arthritis. J Exp Med 1999;189:187-94.
33. Nakamura A, Takai T. A role of FcγRIIB in the development of collagen-induced arthritis. Biomed Pharmacother 2004;58:292-8.